Cancer Genetics announces strategic transactions
Cancer Genetics announced the sale of its BioPharma business to Interpace Diagnostics Group. The purchase price is $23.5 million in addition to the assumption by IDXG of approximately $5 million of liabilities relating to the BioPharma business, before working capital and closing adjustments. July 15, 2019